E Esteve-Palau1, G Solande2, F Sánchez2, L Sorlí2, M Montero2, R Güerri2, J Villar2, S Grau3, J P Horcajada4. 1. Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain; CEXS, Universitat Pompeu Fabra, Universitat Autònoma de Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. Electronic address: esteve.erika@gmail.com. 2. Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain; CEXS, Universitat Pompeu Fabra, Universitat Autònoma de Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain. 3. Pharmacy Service, Hospital del Mar, Barcelona, Spain. 4. Department of Infectious Diseases, Hospital del Mar, Barcelona, Spain; CEXS, Universitat Pompeu Fabra, Universitat Autònoma de Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (IMIM), Barcelona, Spain; CIBERES, Instituto de Salud Carlos III (ISCIII), Madrid, Spain. Electronic address: jhorcajada@parcdesalutmar.cat.
Abstract
OBJECTIVE: To analyze the clinical and economic impact of urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli requiring hospitalization. METHODS: Matched cohort study including adults with UTI caused by ESBL-producing E. coli admitted to a tertiary care hospital in Barcelona, Spain, between August 2010 and July 2013. Demographic, clinical and economic data were analyzed. RESULTS: One hundred and twenty episodes of UTI were studied: 60 due to ESBL-producing E. coli and 60 due to non-ESBL-producing E. coli. Bivariate analysis showed that prior antimicrobial treatment (p = 0.007) and ESBL production (p < 0.001) were related to clinical failure during the first 7 days. Multivariate analysis selected ESBL as the sole risk factor for clinical failure (p = 0.002). Regarding the economic impact of infections caused by ESBL-producing E. coli, an ESBL-producing infection cost more than a non-ESBL-producing E. coli infection (mean €4980 vs. €2612). Looking at hospital expenses separately, the total pharmacy costs and antibiotic costs of ESBL infections were considerably higher than for non-ESBL infections (p < 0.001), as was the need for outpatient parenteral antibiotic therapy (OPAT) and its related costs. Multivariate analysis performed for the higher costs of UTI episodes found statistically significant differences for males (p = 0.004), chronic renal failure (p = 0.025), ESBL production (p = 0.008) and OPAT (p = 0.009). CONCLUSION: UTIs caused by EBSL-producing E. coli requiring hospital admission are associated with worse clinical and economic outcomes.
OBJECTIVE: To analyze the clinical and economic impact of urinary tract infections (UTIs) caused by extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli requiring hospitalization. METHODS: Matched cohort study including adults with UTI caused by ESBL-producing E. coli admitted to a tertiary care hospital in Barcelona, Spain, between August 2010 and July 2013. Demographic, clinical and economic data were analyzed. RESULTS: One hundred and twenty episodes of UTI were studied: 60 due to ESBL-producing E. coli and 60 due to non-ESBL-producing E. coli. Bivariate analysis showed that prior antimicrobial treatment (p = 0.007) and ESBL production (p < 0.001) were related to clinical failure during the first 7 days. Multivariate analysis selected ESBL as the sole risk factor for clinical failure (p = 0.002). Regarding the economic impact of infections caused by ESBL-producing E. coli, an ESBL-producing infection cost more than a non-ESBL-producing E. coli infection (mean €4980 vs. €2612). Looking at hospital expenses separately, the total pharmacy costs and antibiotic costs of ESBL infections were considerably higher than for non-ESBL infections (p < 0.001), as was the need for outpatient parenteral antibiotic therapy (OPAT) and its related costs. Multivariate analysis performed for the higher costs of UTI episodes found statistically significant differences for males (p = 0.004), chronic renal failure (p = 0.025), ESBL production (p = 0.008) and OPAT (p = 0.009). CONCLUSION: UTIs caused by EBSL-producing E. coli requiring hospital admission are associated with worse clinical and economic outcomes.
Authors: Kamrul Islam; Fekade B Sime; Steven C Wallis; Michelle J Bauer; Saiyuri Naicker; Hayoung Won; Hosam M Zowawi; Md Abu Choudhury; Tahmina Shirin; Zakir H Habib; Patrick N A Harris; Meerjady S Flora; Jason A Roberts Journal: Antimicrob Agents Chemother Date: 2022-08-04 Impact factor: 5.938
Authors: Tolbert Sonda; Happiness Kumburu; Marco van Zwetselaar; Michael Alifrangis; Blandina T Mmbaga; Ole Lund; Gibson S Kibiki; Frank M Aarestrup Journal: Eur J Clin Microbiol Infect Dis Date: 2018-07-20 Impact factor: 3.267
Authors: Judith A Anesi; Ebbing Lautenbach; Irving Nachamkin; Charles Garrigan; Warren B Bilker; Jacqueline Omorogbe; Lois Dankwa; Mary K Wheeler; Pam Tolomeo; Jennifer H Han Journal: Infect Control Hosp Epidemiol Date: 2018-10-30 Impact factor: 3.254
Authors: Tolbert Sonda; Happiness Kumburu; Marco van Zwetselaar; Michael Alifrangis; Blandina T Mmbaga; Ole Lund; Frank M Aarestrup; Gibson Kibiki Journal: Eur J Clin Microbiol Infect Dis Date: 2018-02-20 Impact factor: 3.267
Authors: Kathryn L McDonald; Sarah Garland; Carolee A Carson; Kimberly Gibbens; E Jane Parmley; Rita Finley; Melissa C MacKinnon Journal: JAC Antimicrob Resist Date: 2021-02-14
Authors: Dawid Rozenkiewicz; Erika Esteve-Palau; Mar Arenas-Miras; Santiago Grau; Xavier Duran; Luisa Sorlí; María Milagro Montero; Juan P Horcajada Journal: Antibiotics (Basel) Date: 2021-05-15